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        Cardiovascular disease and stroke are major 
causes of morbidity and mortality. Although 
many pathophysiologic processes play a role in 
the chronic development of cardiovascular dis-
ease, thrombosis is often the event that precipi-
tates stroke and acute coronary syndromes. 
Thrombosis is initiated by receptors on resting 
platelets responding to activation initiators such 
as vWf, thrombin, ADP, and collagen. Despite 
the acknowledged principal role of platelet acti-
vation in initiating or exacerbating cardiovascu-
lar disease, there are currently few platelet-specifi  c 
drugs available, making investigation into mech-
anisms of platelet activation very important. 
  After the initiation of platelet activation, 
subsequent pathways are activated, including 
conformational changes in receptors (e.g., GPIIb/
IIIa), granule exocytosis, and the secretion of 
vasoactive mediators. Activation of resting plate-
lets triggers a variety of intraplatelet signaling 
pathways, including changes in intracellular 
ion concentrations such as a burst of intracellu-
lar Na  +   (  1  –  3  ). The primary identifi  ed means of 
increasing intracellular Na  +   is via the Na  +  /H  +   
exchanger (NHE), which is relatively slow and 
does not account for the large rapid increase in 
Na  +   infl  ux (  4, 5  ). It has also been demonstrated 
that membrane depolarization in megakaryo-
cytes and other cells mediates an increase in 
ligand affi   nity and downstream signaling of G 
protein  –  coupled receptors (GPCR), such as 
the platelet purinic receptors (P2Y) ( 6  –  8  ). There-
fore, effi   cient generation of inward currents by 
ion flux may be an important modulator of 
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  Glutamate is an excitatory neurotransmitter that binds to the kainate receptor, the   N  -methyl-
D-aspartate (NMDA) receptor, and the     -amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor (AMPAR). Each receptor was fi  rst characterized and cloned in the 
central nervous system (CNS). Glutamate is also present in the periphery, and glutamate 
receptors have been identifi  ed in nonneuronal tissues, including bone, heart, kidney, pan-
creas, and platelets. Platelets play a central role in normal thrombosis and hemostasis, as 
well as contributing greatly to diseases such as stroke and myocardial infarction. Despite 
the presence of glutamate in platelet granules, the role of glutamate during hemostasis is 
unknown. We now show that activated platelets release glutamate, that platelets express 
AMPAR subunits, and that glutamate increases agonist-induced platelet activation. 
Furthermore, we demonstrate that glutamate binding to the AMPAR increases intracellular 
sodium concentration and depolarizes platelets, which are important steps in platelet 
activation. In contrast, platelets treated with the AMPAR antagonist CNQX or platelets 
derived from GluR1 knockout mice are resistant to AMPA effects. Importantly, mice 
lacking GluR1 have a prolonged time to thrombosis in vivo. Our data identify glutamate 
as a regulator of platelet activation, and suggest that the AMPA receptor is a novel 
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and has a functional role in regulating platelet agonist re-
sponse. Furthermore, mice lacking a complete AMPAR 
have prolonged time to vessel occlusion and platelet function 
in vivo. 
    RESULTS   
  Glutamate release during thrombus generation increases 
platelet activation 
  Platelets store glutamate, express glutamate transporters, and 
release glutamate during activation, but vascular targets of 
glutamate have not been characterized (  13, 14, 16, 24, 25, 33  ). 
To defi  ne the role of platelet-derived glutamate in the vascu-
lature, we fi  rst quantifi  ed platelet glutamate release locally 
within a developing thrombus using a glutamate-sensitive 
enzymatic probe. The probe provides continuous real-time 
glutamate concentration measurements by glutamate oxidase  –
  catalyzed conversion of glutamate to      -ketoglutaric acid and 
hydrogen peroxide. Hydrogen peroxide is then ampomeri-
cally detected (  34  ). We diluted whole blood in Tyrode  ’  s buff  er 
(1:1), and glutamate concentration was measured during 
thrombin-initiated (0.5 U/ml) platelet aggregation. Glutamate 
increases rapidly during platelet aggregation to concentrations 
exceeding 400      M (  Fig. 1, A and B  ).   
  We next determined whether glutamate is a mediator of 
platelet activation. Platelet-rich plasma (PRP) was diluted 1:20 
in Tyrode  ’  s buff  er and incubated with glutamate (0  –  250      M) 
for 5 min before activating platelets with a moderate concen-
tration of thrombin receptor  –  activating peptide (TRAP-6; 
5      M) or a high concentration of TRAP (20      M). Platelet ac-
tivation was measured by FACS analysis for active conforma-
tion of surface GP IIb/IIIa using PAC-1 antibody (  Fig. 2 A  ; 
or by surface P-selectin expression, Fig. S1 B, available at 
platelet response to agonists such as ADP, thrombin, and 
thromboxane. 
  Many molecules and receptors involved in platelet func-
tion also have important roles in neuronal function, including 
exocytosis regulatory molecules, serotonin/serotonin receptor, 
ADP/purinergic receptors, PAR receptors, ApoE/ApoER, 
     -synuclein, acetylcholine, epinephrine, and substance P (  9  –  11  ). 
Platelet-dense granules also contain and release glutamate, 
which is an important neurotransmitter (  12  –  15  ). A major class 
of glutamate receptors includes the ionotropic glutamate re-
ceptors (  N  -methyl-D-aspartate [NMDA], kainate, and      -
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA] 
receptors [AMPARs]). Each receptor has been known to re-
spond to glutamate released from a presynaptic neuron during 
excitatory neurotransmission, but glutamate-mediated signaling 
may also be important in cells that are not commonly consid-
ered excitatory (  16  ). For example, AMPA can stimulate insu-
lin release from       cells in the pancreas, and NMDA receptors 
have been noted in osteoblasts, osteoclasts, and platelets (  17  –  19  ). 
NMDA receptor signaling is reported to have a role in regu-
lating platelet production from megakaryocytes, in addition 
to potentially inhibiting platelet activation (  20  –  23  ). Other sites 
where glutamate receptors have been identifi  ed outside the 
central nervous system (CNS) include the heart, spleen, testis, 
and kidney (  16, 24  ). Several of these peripheral glutamate re-
ceptors have been cloned and sequenced and are identical to 
those in the CNS (  16  ). 
  Blood glutamate concentration is relatively high compared 
with the CNS, and it is tightly controlled by peripheral glu-
tamate transporters (  16  ). Platelets express glutamate uptake 
transporters (EAATs) to clear glutamate from the extracellular 
environment and vesicular glutamate (vGlut) transporters to 
load glutamate into granules (  12, 13, 15  ). Studies primarily 
aimed at using platelets as peripheral markers of CNS diseases 
have demonstrated that glutamate is released upon platelet 
activation (  12, 14, 25, 26  ). After stroke, plasma glutamate 
concentrations rise and remain elevated for up to 2 wk (  14, 27  ). 
Concentrations   >  200      M have been reported in patients upon 
admission for stroke, perhaps contributing to an increased 
thrombotic risk (  25, 27  ). However, functional studies of pe-
ripheral glutamate signaling and its role in vascular physiology 
are limited. 
  Although described in many tissues, AMPAR is best char-
acterized in the brain as a glutamate-sensitive ion channel of 
neuronal activation (  16, 20  ). AMPARs are comprised of het-
eromeric tetramer complexes of subunits designated GluR1  –
  GluR4 (  28, 29  ). The AMPAR subunits combine to form a 
transmembrane receptor with a central ion-permeable channel. 
Glutamate binding to AMPAR triggers Na  +   infl  ux and facili-
tates transduction of an electrical current (  30  ). Calcium per-
meability of the AMPAR is dictated by the GluR2 subunit 
isoform that is present. GluR2 isoform expression varies be-
tween regions of the brain, and with it, AMPAR permeability 
to calcium also varies (  31, 32  ). 
  We now demonstrate the importance of glutamate as a 
modulator of platelet function. AMPAR is expressed on platelets 
    Figure 1.     Glutamate is released in thrombus formation.   (A)  Whole 
blood was diluted in Tyrode  ’  s buffer (1:1), and glutamate concentration 
was measured with a voltage-sensitive enzymatic probe at rest after ad-
dition of PBS (no change) or 0.5 U/ml thrombin (representative tracing). 
(B) Quantifi  cation. Baseline and peak glutamate concentrations during 
thrombus formation.   n   =  3 – 4.  *,  P   <   0.05.   JEM VOL. 205, March 17, 2008 
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dependently increases platelet activation in response to TRAP 
(  Fig. 2 B  ). As little as 150      M of glutamate increases TRAP-
induced platelet activation by   >  50% compared with control-
treated platelets (  Fig. 2 B  ). These are physiologically relevant 
plasma glutamate concentrations; control patient plasma glu-
tamate is     100      M at baseline, and in stroke patients it can 
rise to   >  200      M on admission. Our data in   Fig. 1   (  A and B  ) 
demonstrate that local glutamate concentrations in platelet ag-
gregation can exceed 400      M (  27, 35  ). Glutamate also dose 
dependently increases platelet activation in response to the 
thromboxane mimetic U46619 (  Fig. 2 C  ). 
  Because glutamate appears to have a modulatory role in plate-
let activation, we determined its aff  ects at concentrations that 
are most relevant, low concentrations of glutamate (150      M), 
and low agonist concentrations (1      M TRAP and U46619). 
Glutamate-mediated increase in platelet activation after low 
concentration thromboxane mimetic is approximately three 
times greater than control, and approximately two times greater 
in response to TRAP (  Fig. 2 D  ). 
  Glutamate mediates platelet activation and aggregation 
through the AMPAR 
  We next sought to identify the glutamate receptor that aug-
ments platelet activation. Others have demonstrated the pres-
ence of the NMDA type glutamate receptor (NMDAR) on 
platelets, but this appears to have a diff  erent role in platelet 
function (  20, 22, 23  ). To determine whether NMDAR me-
diates glutamate activity, we blocked the NMDAR with 
(  ±  )-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) 
and treated platelets with glutamate before stimulating with 
TRAP. NMDAR inhibition does not inhibit glutamate-
  mediated increase in platelet activation (  Fig. 3 A  ).   We therefore 
explored whether platelets express another type of ionotropic 
glutamate receptor. We demonstrated the presence of AMPAR 
subunit proteins GluR1-4 by immunoblot (  Fig. 3 B  ). We also 
localized expression of the AMPAR subunit GluR1 to the 
platelet surface using fl  ow cytometry (FACS) with an anti-
body specifi  c for an external region of GluR1 (  Fig. 3 C  ). These 
data demonstrate that platelets express the AMPAR. 
  To defi  ne AMPAR  ’  s potential role as a mediator of platelet 
activation, we incubated PRPs with control or AMPA (0.1   –   
1 mM) and activated the platelets with TRAP. Similar to 
glutamate, pretreatment of platelets with AMPA has no aff  ect 
on resting platelets, but dose dependently increases agonist-
induced platelet activation (  Fig. 4 A  ).   AMPA also increases 
platelet activation in response to U46619 (Fig. S1 C). 
  We next used additional pharmacological approaches to 
demonstrate signaling through the AMPAR and its potential 
as a target for antithrombotic therapy. First, we incubated 
human platelets with control, the AMPAR inhibitor CNQX 
(100      M), AMPA, or both, and then we measured platelet 
activation in response to TRAP. CNQX is an AMPAR inhibi-
tor with some kainate receptor blocking, but has a 20  –  150-
fold selectivity for AMPAR subunits versus kainate receptor 
subunits. As before, AMPA increases TRAP-induced PAC-1 
antibody binding (  Fig. 4 B  ). CNQX inhibits TRAP-induced 
http://www.jem.org/cgi/content/full/jem.20071474/DC1).   
Glutamate does not increase resting platelet activation (  Fig. 2 A  ), 
but in the presence of glutamate, 5      M of TRAP signifi  -
cantly increases platelet activation (  Fig. 2 A  ). Glutamate has 
no eff  ect at high TRAP concentrations (  Fig. 2 A  ). A dose  –
  response curve with glutamate and moderate TRAP con-
centration (5      M) was also performed, and PAC-1 binding 
was expressed as the percentage of increase in platelet mean 
fl  uorescence versus resting control platelets. Glutamate dose 
    Figure 2.     Glutamate mediates platelet activation.   (A)  Glutamate 
increases platelet activation. Platelets were incubated with glutamate and 
activated with a moderate concentration of TRAP (5   μ  M) or high concen-
tration of TRAP (20   μ  M). Activation was measured by FACS analysis for 
surface PAC-1 antibody binding.   n   = 4   ±   the SD. *, P   <   0.02 versus 0.5   μ  M 
TRAP. (B) Dose response. Platelets were incubated with glutamate and 
activated with a moderate concentration of TRAP (5   μ  M). Activation was 
measured by FACS analysis for surface PAC-1 antibody binding and 
  expressed as the percentage of increase in fl  uorescence versus resting 
platelets.   n   = 5  –  7   ±   the SD. *, P   <   0.01 versus 0. (C) AMPAR regulates 
platelet activation. Glutamate increases thromboxane mimetic-induced 
(U46619; 10   μ  M) platelet activation measured by PAC-1 antibody binding. 
  n   = 3   ±   the SD. *, P   <   0.01 versus 0   μ  M. (D) Glutamate is highly effective 
at low-dose agonist stimulation. Platelets were incubated with 150   μ  M 
glutamate and activated with 1   μ  M TRAP or U46619.   n   = 5   ±   the SD. 
*, P   <   0.05; **, P   <   0.01 versus control.     578 GLUTAMATE SIGNALS THROUGH PLATELET AMPAR | Morrell et al.
surface membrane (  Fig. 4 D  ). However, WT platelets stimu-
lated with thrombin have a greater increase in P-selectin ex-
ternalization than GluR1       /       platelets. Furthermore, AMPA 
increases activation of WT platelets, but not GluR1       /       plate-
lets (  Fig. 4 D  ). 
  Collectively, these data demonstrate that AMPAR signal-
ing increases platelet activation. 
  Platelet AMPAR signaling induces sodium infl  ux
and platelet depolarization 
  In the open state, AMPARs are permeable to Na  +  , and de-
pending on its subunit isoform composition, can also be se-
lectively permeable to Ca  2+  . To determine if platelet AMPAR 
increases Na  +   infl  ux into platelets, we preincubated platelets 
with the Na  +  -sensitive dye sodium-binding benzofuran isoph-
thalate (SBFI) and added control, AMPA (1 mM), CNQX 
(100      M), or both. Platelets were then activated or not acti-
vated with TRAP. AMPA increases intracellular Na  +   concen-
tration by approximately twofold upon activation, as compared 
with control (  Fig. 5 A  ).   CNQX not only decreases Na  +   con-
centrations in platelets treated with both AMPA and TRAP, 
but CNQX also decreases Na  +   levels in platelets treated 
with TRAP alone (  Fig. 5 A  ). These data demonstrate that the 
AMPAR mediates an increase in intracellular Na  +  . 
  To confi  rm that the AMPAR mediates Na  +   infl  ux inde-
pendent of the NHE, we inhibited the NHE with 100      M 
amiloride (Fig. S1 F), and activated platelets or not with TRAP. 
platelet activation and inhibits the eff  ects of AMPA upon plate-
let stimulation (  Fig. 4 B  ). Furthermore, as little as 10      M of 
CNQX signifi  cantly decreases platelet activation, likely by 
inhibition of released endogenous glutamate activities, indi-
cating an autocrine role of glutamate in platelet activation 
(  Fig. 4 C   and Fig. S1 D). Other AMPAR inhibitors, such as 
NBQX, have similar eff  ects (Fig. S1 E). 
  The functional relevance of platelet AMPAR was ex-
plored by isolating platelets from WT and GluR1 subunit 
knockout mice (GluR1       /      ). Platelets from each type of mouse 
were incubated with vehicle or AMPA (1 mM) and activated 
or not activated with thrombin (0.25 U/ml). Unstimulated 
platelets from WT and GluR1       /       mice have similar levels of 
activation, as measured by P-selectin localized to the platelet 
    Figure 3.     Platelets express the AMPAR.   (A) Glutamate does not act 
through the NMDA receptor. Platelets were incubated with control, gluta-
mate, or glutamate after the NMDA receptor inhibitor CPP, and then 
activated or not with TRAP.   n   = 3   ±   the SD. *, P   <   0.05 versus 0 mM. 
(B) Platelets express AMPAR subunits. Human platelet and mouse brain 
lysates were immunoblotted for AMPAR subunit proteins GluR1  –  4. 
(C) GluR1 is localized to the surface of platelets. Platelets were incubated 
with control IgG or GluR1 antibody and surface expression assayed by 
FACS (representative of three experiments with similar results).     
    Figure 4.     AMPAR signaling mediates platelet activation  . (A) AMPA 
dose dependently increases agonist-induced platelet activation. Platelets 
were incubated with AMPA and activated with TRAP. Platelet activation 
was measured by FACS analysis for surface PAC-1 antibody binding. 
  n   = 5   ±   the SD. *, P   <   0.05 versus 0 mM. (B) AMPAR antagonist inhibits 
AMPA-mediated increase in platelet activation. Platelets were incubated 
with control, CNQX, AMPA, or AMPA after CNQX, and then activated with 
TRAP.   n   = 3   ±   the SD. *, P   <   0.05. (C) AMPAR antagonist decreases platelet 
activation. Platelets were incubated with control or CNQX, and then acti-
vated or not with TRAP.   n   = 5   ±   the SD. *, P   <   0.05. (D) GluR1      /      platelets 
do not respond to AMPA. Platelets from WT and GluR1      /      mice  were 
incubated with control or AMPA, and activated with 0.25 U/ml thrombin 
(Thr).   n   =  3   ±   SD.  *,  P   <   0.05.   JEM VOL. 205, March 17, 2008 
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the application and subsided to a steady-state value (  Fig. 5 C  ). 
To further demonstrate that the current induced by AMPA 
was mediated by activation of AMPARs, bone marrow mega-
karyocytes were isolated and electrophysiologic recordings 
performed in parallel using cells from a single megakaryocyte 
isolation. Administration of the AMPAR antagonist CNQX 
(30      M) blocks the AMPA-induced current (  n   = 6;   Fig. 5 E   
and Fig. S1 J). 
  We next sought to determine the reversal potential of the 
current induced by AMPA and kainate by determining the 
current  –  voltage relationship of the agonist-induced inward 
current. In the case of AMPA application, it was somewhat 
diffi   cult to reliably and reproducibly match the voltage steps 
with the short-lived peak current obtained at the very begin-
ning of the application (  Fig. 5 C  ). As a consequence, I  –  V 
curves were constructed from the delayed, steady-state part 
of the AMPA-induced current. In these conditions, the current 
induced by both AMPA (  n   = 5) and kainate (  n   = 5) reversed 
at a potential close to 0 mV and did not show any obvious 
Inhibition of the NHE reduces Na  +   infl  ux and platelet activa-
tion in response to TRAP (  Fig. 5 B   and Fig. S1 G). However, 
adding AMPA after amiloride restores Na  +   infl  ux and platelet 
activation, again suggesting that the AMPAR can act as a Na  +   
channel in platelet activation (  Fig. 5 B  ). 
  To further characterize the signaling induced by platelet 
AMPAR activation, we performed electrophysiological re-
cordings from bone marrow  –  isolated megakaryocytes. Whole-
cell recordings showed that rapid application of AMPA (0.1 or 
1 mM;   n   = 7; not depicted) or kainate (kainate; 0.1 or 1 mM; 
  n   = 3) did not induce a measurable current. In contrast, when 
the desensitization blocker cyclothiazide was included in the 
recording solution, a small but reproducible inward current 
was readily observed after rapid perfusion of AMPA (100      M; 
12.9   ±   the SEM 7.1 pA;   n   = 9;   Fig. 5 C  ) and kainate (100      M; 
4.8   ±   SEM 1.4 pA;   n   = 7;   Fig. 5 D  ). Whereas the inward 
current induced by kainate was of sustained amplitude through-
out the duration of the application, that induced by AMPA 
was typically of slightly greater amplitude at the beginning of 
    Figure 5.     Platelet AMPAR mediates sodium transport.   (A) AMPA increases intracellular sodium. Platelets were loaded with SBFI; treated with 
  control, AMPA, CNQX, or AMPA after CNQX; and activated with TRAP. Change in intracellular sodium was measured by FACS.   n   = 3   ±   the SD. *, P   <   0.05 
versus control. (B) AMPAR increases Na  +   infl  ux independent of NHE. Platelets were treated with control, amiloride, AMPA, or amiloride before AMPA. 
 Intracellular  Na +   was determined by FACS.   n   = 3   ±   the SD. *, P   <   0.05. (C) Fast application of AMPA to megakaryocytes induces a rapid inward current that 
reverses close to 0 mV. (top) A current trace showing an inward current induced by fast application of AMPA (time of application shown by the solid line). 
Rapid current steps for determining I  –  V relationships were applied before (not depicted) and during application of AMPA (rapid current defl  ection, black 
dots). (bottom) The I  –  V relationship obtained for the AMPA-induced current. The plot represents the averaged I  –  V curves obtained from 5 different cells, 
normalized to the current obtained at      60 mV. (D) Fast application of kainate to megakaryocytes induced a rapid inward current that reversed close to 0 mV. 
(top) A current trace and the averaged I  –  V curves for kainate application are shown on the bottom. (E) The inward current induced by 100   μ  M AMPA was 
blocked by administration of the AMPAR antagonist CNQX (30   μ  M;   ±   the SD) *, P   <   0.05. (F) JST had no effect on the AMPA- triggered increase in platelet 
activation. Platelets were incubated with 1   μ  M JST and activated or not with TRAP.   n   =  3   ±   the  SD.   580 GLUTAMATE SIGNALS THROUGH PLATELET AMPAR | Morrell et al.
  These data demonstrate that platelet AMPAR presents a 
potential novel in vivo therapeutic target. We therefore per-
formed in vivo studies to support this idea. We treated mice 
i.v. with control PBS or CNQX (0.1 mg/kg), and 20 min 
later, tail bleeding times were determined. Control mice have 
a mean bleeding time of     200 s, with a cluster of mice that have 
very similar bleeding times ( Fig. 8 A ).   AMPAR inhibitor –  treated 
rectifi  cation (  Fig. 5, C and D  ). Together, the results from these 
electrophysiological recordings support our previous fi  nding 
in showing that megakaryocytes express functional AMPARs 
on their surface. In addition, the linear current  –  voltage relation-
ship suggests that these receptors are GluR2 subunit  –  contain-
ing AMPARs. 
  In addition to conferring a linear I  –  V relationship to the 
AMPAR complex, the incorporation of GluR2 subunit ren-
ders the AMPAR impermeable to calcium. Joro spider toxin 
(JST) allows pharmacological discrimination between these 
subtypes of AMPARs by selectively inhibiting GluR2 Ca  2+  -
permeable AMPARs (  36  ). We next incubated platelets with 
1      M JST before AMPA. JST preincubation had no eff  ect on 
AMPA-mediated increase in platelet activation (  Fig. 5 F  ). Thus, 
these results suggest that platelet AMPARs are of the GluR2-
containing, Ca  2+  -impermeable AMPAR subtype. 
  Collectively, these data suggest that the AMPAR modu-
lates platelet activation in part by regulating Na  +   infl  ux. 
  AMPAR increases platelet activation in response
to GPCR agonists 
  Others have demonstrated an increase in GPCR ligand affi   nity 
and activity subsequent to membrane depolarization (  6  –  8  ). 
Glutamate increases both thrombin and thromboxane receptor 
(both GPCR) agonist-induced platelet activation. To deter-
mine if it similarly increases platelet activation in response to 
other GPCR agonists, platelets were incubated with glutamate 
(250 and 500      M) before activation with epinephrine, which 
is a GPCR ligand, or collagen, which is a non-GPCR ligand. 
Glutamate signifi  cantly increases epinephrine-induced platelet 
activation (  Fig. 6 A  ), but has no eff  ect on collagen-induced 
platelet activation (  Fig. 6 B  ).   As further proof, we activated 
platelets with ATP in the presence of glutamate. ATP stimu-
lates platelet P2X  1  , which is a purine-dependent, ligand-gated 
ion channel for Ca  2+   (  37  ). ATP-mediated platelet activation 
is not increased by glutamate (  Fig. 6 C  ). Platelet P2Y receptors 
are GPCR purine-dependent receptors, and activation of plate-
lets by the P2Y-specifi  c agonist 2-Me-ADP is increased by 
glutamate (  Fig. 6 D  ). These data support the idea that platelet 
AMPAR activation increases GPCR ligand signaling activity. 
  AMPAR inhibition blocks aggregation and delays
in vivo thrombosis 
  The functional relevance of targeting platelet AMPAR signaling 
was assayed by fi  rst measuring aggregation in response to TRAP 
(10      M) after incubating platelets with control or CNQX 
(1  –  100      M). CNQX dose dependently reduces platelet aggre-
gation (  Fig. 7, A and B  ).   Exogenous AMPA (1 mM) was also 
added to platelets before aggregation. AMPA increases the rate 
of early aggregation. At 1 min after TRAP, control platelets are 
    55% aggregated and AMPA-pretreated platelets are     75% ag-
gregated (  Fig. 7 C  ). At later time points, the eff  ect is less apparent 
(  Fig. 7 C  ), which is likely a refl  ection of the large concentration 
of endogenous glutamate released into the growing platelet ag-
gregate obscuring exogenous AMPA eff  ects with time. 
    Figure 6.     Glutamate mediates an increase in GPCR signaling.  
(A) Glutamate increases epinephrine-mediated platelet activation. 
  Epinephrine-induced (10   μ  M) platelet activation was measured by PAC-1 
antibody binding.   n   = 5   ±   the SD. *, P   <   0.01 versus 0   μ  M. (B) Glutamate 
does not effect collagen-mediated platelet activation. Platelets were incu-
bated with glutamate and activated with collagen. Activation was mea-
sured by FACS analysis for surface PAC-1 antibody binding.   n   = 5   ±   the SD. 
(C) Glutamate does not increase ATP-induced platelet activation. ATP 
induced platelet activation was measured by PAC-1 antibody binding. 
  n   = 5   ±   the SD. (D) Glutamate increases P2Y-mediated platelet activation. 
The P2Y agonist 2-Me-ADP-induced platelet activation was measured by 
PAC-1 antibody binding.   n   = 5   ±   the SD. *, P   <   0.01 versus 0   μ  M.     JEM VOL. 205, March 17, 2008 
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inhibitor, mice lacking GluR1 have prolonged time to vessel 
occlusion compared with WT control mice (  Fig. 8 D  ). 
    DISCUSSION   
  The major fi  ndings of our study are that AMPARs modulate 
platelet activation and thrombosis. These results have important 
implications for thrombotic diseases such as stroke, where 
plasma glutamate levels can rise signifi  cantly (  25, 27  ). After 
compromise of the blood  –  brain barrier, glutamate released by 
neurons or platelets may contribute to the pathophysiology of 
stroke, not only as an excitatory amino acid but also by acting as 
a prothrombotic messenger. The importance of these results is 
not limited to cerebral vascular disease. We show that large con-
centrations of glutamate are released locally in platelet aggre-
gation, making glutamate signaling important in disease processes 
such as myocardial infarction and ischemia-reperfusion injury. 
AMPAR antagonists may therefore be useful in the treatment 
and prevention of stroke, myocardial infarction, and other throm-
botic diseases. 
  We propose that glutamate contained within platelet-
dense granules is released in high concentrations locally into 
  “  the platelet synapse  ”   as platelets come into close apposition 
during thrombus formation. This glutamate released into the 
formed platelet synapse early in platelet activation acts in an 
mice have a prolonged mean bleeding time (    600 s) and a 
greater range of bleeding times (  Fig. 8 A  ). 
  To confi  rm these data, we used intravital microscopy to 
examine the role of platelet AMPAR signaling in thrombus 
formation. Platelets were isolated from control mice, fl  uores-
cently labeled, and injected i.v. into recipient mice. Mice 
were then treated with CNQX or control PBS intravenously 
20 min before mesentery externalization and FeCl  3   application. 
Images were collected to quantify in vivo platelet function 
(  Fig. 8 B  ). Compared with PBS-treated mice, mice treated 
with CNQX have prolonged time to platelet adhesion (  >  10 
platelets adherent for   >  10 s), thrombus formation (fi  rst stable 
thrombus   >  20      m), and total vessel occlusion (  Fig. 8 C  ). 
  To determine if mice lacking the AMPAR subunit GluR1 
have in vivo changes in platelet function, isolated platelets 
from WT control or GluR1       /       mice were fl  uorescently labeled 
and injected into mice of the same genotype. Mesenteric arte-
rioles were then damaged with FeCl  3  , and thrombus formation 
was again imaged. Similar to mice treated with the AMPAR 
    Figure 7.     AMPAR signaling mediates platelet aggregation.   (A)  AMPAR 
inhibition decreases platelet aggregation. Platelets were incubated with 
control or CNQX and activated with 10   μ  M TRAP. Platelet aggregation 
was measured by an aggregometer. (B) Quantifi  cation. AMPAR inhibition 
decreases platelet aggregation.   n   = 5  –  12   ±   the SD. *, P   <   0.01. (C) Exogenous 
AMPA increases early platelet aggregation.   n   = 5   ±   the SD. *, P = 0.03; 
NS, P = 0.09.     
    Figure 8.     AMPAR mediates platelet function in vivo.   (A)  AMPAR 
inhibition with 0.1 mg/kg CNQX prolongs bleeding time in vivo. *, P   <   0.01 
versus control. (B) FeCl  3   was placed on externalized mesenteric arterioles, 
and platelets were imaged using intravital microscopy (representative 
images 400 s after FeCl  3  ). Bars, 25   μ  m. (C) AMPAR inhibition with 0.1 mg/kg 
CNQX prolongs platelet adherence, thrombus formation, and vessel occlu-
sion in vivo. *, P   <   0.05; **, P   <   0.01 versus control. (D) GluR1      /      mice 
have prolonged time to vessel occlusion in vivo. *, P   <   0.02 versus WT. 
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cells, however, are similar to megakaryocytes in that AMPAR-
mediated inward currents are only observed in the presence of 
cyclothiazide (  41  ). Several mechanisms may account for these 
cell type  –  specifi  c biophysical properties of AMPARs. For in-
stance, transmembrane AMPAR-regulating proteins are im-
portant modulators of AMPAR functions, and their diff  erential 
expression among cell types is expected to translate into diff  er-
ent functional properties of AMPARs (  35, 42  ). Future studies 
will be required to directly address this possibility. 
  There have been few reports of the NMDA receptor on 
platelets and megakaryocytes (  20  –  23  ). Signaling through the 
NMDA receptor has been demonstrated to increase platelet 
production from megakaryocytes (  20, 23  ), and interestingly, 
NMDA receptor signaling in platelets has been shown to inhibit 
platelet aggregation (  21, 22  ). We now show that glutamate-
  mediated increase in platelet activation is independent of the 
NMDA receptor (  Fig. 3 A  ). Prior NMDA receptor studies 
  primarily used aggregation as the measure of platelet function, 
but endogenous platelet glutamate must be taken into account. 
We demonstrate that a substantial concentration of glutamate is 
released in the developing thrombus that reaches peak levels 
very rapidly (  Fig. 1  ), and in our studies, exogenous glutamate 
or AMPA addition has no eff  ect on fi  nal aggregation, likely be-
cause the rapid release of endogenous glutamate obscures any 
eff  ect. However, the NMDAR studies do raise important ques-
tions for future research. NMDAR signaling in neurons is a ma-
jor means to regulate AMPAR traffi   cking by inducing an infl  ux 
of Ca  2+   that initiates the delivery of AMPARs from the recy-
cling endosome to the surface membrane. Prior NMDAR stud-
ies in platelets demonstrate that NMDA induces an increase in 
Ca  2+   infl  ux, and as a result may mediate an increase in AMPAR 
surface localization (  21, 22  ). 
  Other glutamate regulatory elements in platelets, such as 
the glutamate transporters (EAATs), have primarily been 
studied as peripheral markers of CNS disease. However, 
EAATs and other glutamate receptors may also have an 
  important role in normal platelet function by controlling the 
plasma glutamate concentration. Individuals with polymor-
phisms in EAAT-2 have increased plasma glutamate concen-
trations with a higher frequency of early neurological worsening 
in stroke (  27  ). It is interesting to consider that these individuals 
may also be at increased risk of stroke, or that increased neu-
rological decline may be secondary to continued platelet ac-
tivation and increased infarct size. Further study is needed to 
fully appreciate glutamate in the periphery and its relevance 
to thrombosis. 
    MATERIALS AND METHODS   
  Reagents 
  L-glutamate, AMPA, CPP, ADP, CNQX:HBC, mouse thrombin, choline 
chloride, amiloride, U46619, and JST were purchased from Sigma-Aldrich. 
Antibody to GluR1 was purchased from Calbiochem; antibodies to GluR2, 
GluR3, and GluR4 were purchased from Santa Cruz Biotechnology. PAC-1 
and P-Selectin antibodies were purchased from BD Biosciences. FITC-IgG 
secondary antibody for FACS, SBFI, and BCEF were purchased from Invit-
rogen. RT-PCR reagents were purchased from Invitrogen. TRAP-6 was 
purchased from Bachem. 
autocrine manner to promote complete platelet activation 
and in a paracrine fashion to rapidly increase the agonist sen-
sitivity of recruited platelets. This helps drive and accelerate 
further thrombus formation. This model is supported by our 
data demonstrating that glutamate increases platelet sensitivity 
to low-dose agonist stimulation, that AMPAR antagonists in-
hibit platelet function, and that mice lacking the AMPAR 
subunit GluR1 have prolonged time to vessel occlusion. Our 
data does not rule out potential contributions of AMPARs 
expressed by other vascular cells, or the potential contribution 
of other platelet-expressed glutamate receptors, such as kainate 
receptors or metabotropic glutamate receptors. Taken as a 
whole, however, our ex vivo and in vivo data demonstrate an 
important role for platelet glutamate and AMPAR in platelet 
activation and thrombus formation. 
  Glutamate function in thrombosis is very similar to that of 
another neurotransmitter, serotonin (5-HT). At basal condi-
tions, plasma 5-HT is relatively low and tightly regulated, but 
is rapidly released from dense granules upon platelet activation. 
Serotonin promotes continued platelet aggregation, as indicated 
by mice lacking the enzyme necessary for peripheral 5-HT 
production having prolonged time to vessel occlusion (  38, 39  ). 
Similar to glutamate, 5-HT is a weak platelet agonist on its own 
and its eff  ect is enhanced by the addition of other agonists (  40  ). 
Serotonin reuptake inhibitors may provide myocardial infarc-
tion protection, but have not been extensively studied or used 
clinically as a preventative therapy (  39  ). 
  We demonstrate that glutamate mediates an increase in 
platelet activation in response to the GPCR agonists thrombin, 
thromboxane, epinephrine, and ADP. However, glutamate has 
no eff  ect on non-GPCR signaling pathways, such as through 
the collagen or P2X receptors. We also show that AMPAR 
signaling increases platelet Na  +   infl  ux and induces an inward 
current that depolarizes megakaryocyte membranes. Membrane 
depolarization can lead to an increase in GPCR ligand affi   n-
ity by creating a charge movement that increases G protein 
coupling with the GPCR (  8, 37  ). Platelet G protein receptors 
contain positively charged internal amino acid regions that 
are possible voltage-sensing domains, providing further support 
to our hypothesis. Alternatively, independent of a potential 
depolarization function, Na  +   is an important ion in platelet 
activation. A rapid increase in intracellular Na  +   is necessary to 
drive the Na  +  /Ca  2+   exchanger and promote calcium-mediated 
events in platelet activation. The primary function of platelet 
AMPAR may be simply as a rapid sodium channel. Future 
studies are needed to determine the key regions of platelet 
GPCRs that AMPAR signaling and membrane depolarization 
may act upon to increase platelet activation. 
  Our electrophysiological studies support our data by show-
ing that megakaryocytes express functional, most likely GluR2-
containing, Ca  2+  -impermeable AMPARs. Notably, the inward 
current induced by AMPA application in megakaryocytes was 
of modest amplitude and only observed in the presence of a 
desensitization blocker, cyclothiazide. This contrasts with neu-
rons where robust AMPAR-mediated inward currents are 
readily observed in the absence of cyclothiazide. Microglial JEM VOL. 205, March 17, 2008 
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  Electrophysiological studies.     Whole-cell recordings were obtained from 
freshly isolated megakaryocytes using an intracellular solution of the following 
composition: 150 mM CsCl, 1 mM EGTA, and 10 mM Hepes. The pH was 
adjusted to 7.3 using NMDG-OH. The patch-clamp procedures were similar 
to those previously described (  43  ). In brief, the experiments were performed in 
the tight-seal whole-cell confi  guration at room temperature, and electrical sig-
nals were acquired with an EPC-7 (HEKA). The pipette resistances ranged be-
tween 2 and 3 M     . 
  Current  –  voltage relationships (I  –  V curves) were obtained by clamping 
the cell to diff  erent potentials in 30-mV increments (     30, 0, and + 30 mV; 
each for 35 ms) from a holding potential of      60 mV. I  –  V curves obtained 
before the application of the agonists were subtracted from those (typically 
two) obtained in the presence of the agonists. The current responses were 
monitored on a chart recorder (WR7700; Graphtec) through a low-pass 
  fi  lter (200 Hz). Chemicals and reagents used were purchased from either 
Sigma-Aldrich or Wako Pure Chemicals. 
  Rapid perfusion of AMPA and Kainate was achieved by puff   application 
from a nearby pipette of 30  –  35      m diam to an isolated single megakaryocyte. 
The perfusion pipette was located within 30      m of the cell, and the puff   pres-
sure was adjusted to obtain rapid and eff  ective agonist application (  <   10 ms). 
    Fig. 5 E   was performed using two bathing chambers (test and control) 
placed on the stage of an inverted microscope. One chamber contained a 
megakaryocytes immersed in Na  +  -ES  –  containing CNQX (test chamber), 
and the other contained the same batch of megakaryocytes immersed in 
Na  +  -ES alone (control chamber). Traces used in the I  –  V curve were those 
which had good signal-to-noise ratio during the voltage steps. 
  Data analysis 
  Data are expressed as the mean   ±   the SD, unless otherwise stated. Statistical 
comparisons between two groups were performed using the Student  ’  s   t   test. 
  Online supplemental material 
  Fig. S1 shows glutamate probe calibration (A), data related to glutamate stimula-
tion of platelet activation (B and C), AMPAR antagonist data (D and E), 
amiloride blocking of NHE (F and G), and inward current tracings (H  –  J). 
The online version of this article is available at http://www.jem.org/cgi/content/
full/jem.20071474/DC1. 
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